Deleted Tweets From Scott Gottlieb, R-D.C.
Scott Gottlieb's accounts: SteveFDA
Tracked Between: October 20, 2017-January 20, 2021
SteveFDA (R-D.C.)
@SGottliebFDA
RT @washingtonpost: FDA’s Gottlieb calls for greater use of medication-assisted treatment to fight opioid epidemic https://t.co/cBqMxaNlkK
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: Bloomberg: FDA, FTC Promise United Effort to Fight Expensive Drugs https://t.co/EhOF41cmTN
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: Report: "FDA eyes even more pricing competition with another round of generics moves" -- https://t.co/7MGL61Gw0w
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA approved more generics in a single month than ever before (101 in Oct. 2017), improving access to affordable d… https://t.co/1yxt31Cn4T
SteveFDA (R-D.C.)
@SGottliebFDA
FDA guidance on menu labeling is open for public comment. We welcome opportunity to work with stakeholders, includi… https://t.co/refMHbdDGH
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAMedia: FDA issues advisory about the deadly risks associated with the use of kratom, a botanical substance that has simila… https://t.co/kWS85q9dL1
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA issues warning on risks associated with Kratom and details enforcement strategy related to opioids in new docu… https://t.co/lO4kGuIWXP
SteveFDA (R-D.C.)
@SGottliebFDA
RT @Reuters_Health: FDA raises concerns about use of kratom for opioid addiction https://t.co/GOJC1tGrqK https://t.co/6yFFxmI0kS
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA must protect public from addictive substances like kratom; as part of our commitment to stemming opioid epidem… https://t.co/OWWYdXsUes
SteveFDA (R-D.C.)
@SGottliebFDA
We’ve learned a tragic lesson from opioid crisis: #FDA must pay early attention to potential for new products like… https://t.co/JFcy1qlvSu
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA warns about serious injuries that can result from using injectable silicone or products falsely marketed as FD… https://t.co/774cuOTIPN
SteveFDA (R-D.C.)
@SGottliebFDA
RT @califf001: Glad to see this. https://t.co/P2Wx4U6vIT QT @US_FDA: We’ve learned a tragic lesson from the opioid crisis. We must pay early attention to the potential for new products… https://t.co/4OR89j50cO)
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA is actively working with our partners at the Drug Enforcement Administration to further evaluate kratom and de… https://t.co/fHFd9bZVEs
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: #FDA issues warning on risks associated with Kratom and details enforcement strategy related to opioids in new docu… https://t.co/lO4kGuIWXP
SteveFDA (R-D.C.)
@SGottliebFDA
RT @US_FDA: No injectable filler is FDA-approved for large-scale body enhancement. Here’s why you should avoid injectable silic… https://t.co/kKXdlW32Xd
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDA_MCMi: Currently, Resistome Tracker is focused on antibiotic resistance genes in Salmonella w/ data uploaded weekly… QT @SGottliebFDA: FDA launches Resistome tracker -one of the 1st publicly available tools to provide visual displays of… https://t.co/taLpPDC1Ua)
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: #FDA is actively working with our partners at the Drug Enforcement Administration to further evaluate kratom and de… https://t.co/fHFd9bZVEs
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: FDA launches Resistome tracker -one of the 1st publicly available tools to provide visual displays of… https://t.co/taLpPDC1Ua
SteveFDA (R-D.C.)
@SGottliebFDA
RT @CGrantWSJ: This is a very interesting piece and it recalls the recent “end the shenanigans” comments from @SGottliebFDA https://t.co/uF… QT @profmikecarrier: Fed up with high drug prices? My @WSJopinion highlights 4 things Congress can do: help generics get samples, make c… https://t.co/Xcy111Sufo)
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: FDA permits marketing of the first device for use in helping to reduce the symptoms of opioid withdrawal: https://t.co/LW1FVQLbx7